benazepril and Weight-Gain

This study compared the effect of benazepril, an angiotensin converting enzyme inhibitor to valsartan, an angiotensin AT1 receptor antagonist, on glucose tolerance in the conscious, spontaneously hypertensive rat. Intraperitoneal infusion of benazepril or valsartan at 1, 3 and 10 mg/kg per day produced equivalent dose-related reductions in systolic blood pressure for 12 weeks. Body weight gain during the treatment period was significantly reduced by infusion rates of benazepril. In contrast, only the highest infusion rate of valsartan significantly affected body weight gain. At the end of the 12-week treatment period, neither benazepril nor valsartan significantly affected glucose disposal during intravenous glucose tolerance tests. The insulin response to glucose challenge was unaffected by valsartan whereas following the highest infusion rate of benazepril the plasma levels were significantly reduced. The results demonstrate that benazepril but not valsartan reduces the insulin required to dispose of a glucose load.

Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Glucose; Blood Pressure; Body Composition; Glucose Tolerance Test; Insulin; Male; Rats; Rats, Inbred SHR; Tetrazoles; Valine; Valsartan; Weight Gain